Cytomegalovirus Viraemia
4
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Personalised Dosing Of Iv Ganciclovir
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress
Research Network
Common Treatments
- Personalised Dosing Of Iv Ganciclovir1
- Quantiferoncmv Assay1
- Standard Dosing Of Iv Ganciclovir1
- Valganciclovir Or Ganciclovir1
Active Sponsors
- University Health Network, Toronto2
- Canadian National Transplant Research Program1
- University of Athens1
- Murdoch Childrens Research Institute1
Top Investigators
University Health Network, Toronto
University Health Network, Toronto
Univeristy of Athens , Greece
Murdoch Childrens Research Institute
Related Conditions
- Stress Physiological1
- Receptor Hormonal Disorder1
- Other Deficiency Of Cellmediated Immunity1